Gabriel Morris
| Gabriel Morris | |
|---|---|
 File:Gabriel Morris.jpeg | |
| Born | United States |
| 🏡 Residence | Los Angeles, California, United States |
| 🏳️ Nationality | American |
| 🏫 Education | Columbia University (B.A. in Economics, 2008); Vanderbilt University |
| 💼 Occupation | Biotechnology executive, financial professional, investor |
| 📆 Years active | 2008–present |
| 👔 Employer | Immix Biopharma, Inc. |
| Known for | President, Chief Financial Officer and Director of Immix Biopharma |
| Title | President, Chief Financial Officer and Director |
| 🌐 Website | www.gabriel.bio |
Gabriel Morris is an American biotechnology executive, investor and financial professional. He is the President, Chief Financial Officer and a member of the board of directors of Immix Biopharma, Inc.. Morris joined the company's executive leadership as CFO and director in March 2021 and was appointed President in March 2026. He also serves as Managing Partner of Alwaysraise LLC, a life sciences investment and advisory firm, and is a co-founder of Nexcella, Inc.
At Immix Biopharma, Morris is involved in corporate management, financial planning, business development, corporate strategy, investor relations and financing activities. He became associated with the company after meeting its founder, Ilya Rachman, in 2020, subsequently investing in the business before its initial public offering and joining its leadership team.
Early life and education
Morris grew up in Tennessee, United States. His early academic interests included science and medicine, and he published research in the Journal of Biological Chemistry before beginning his university education. He was accepted into the Humanities and Medicine programme at the Icahn School of Medicine at Mount Sinai, although he later pursued a career combining biotechnology, investment and corporate finance.
He attended Vanderbilt University in Tennessee for one year as a Vanderbilt University College Scholar before transferring to Columbia University in New York City. In 2008, he graduated from Columbia with a Bachelor of Arts degree in economics.
During his undergraduate years, Morris participated in the Humanities and Medicine programme at the Icahn School of Medicine at Mount Sinai and contributed to experimental scientific research published in peer-reviewed journals. His academic activities also included recognition on the Dean's List and participation in the Columbia Emerging Leaders Program.
Career
Investment banking and financial services
Morris began his professional career in investment banking in 2008. From 2008 to 2018, he worked on cross-border mergers and acquisitions at Goldman Sachs & Co. and other international investment banks.
During this period, he participated in completed transactions with an aggregate value exceeding US$50 billion. His work involved international corporate transactions, financial structuring and investment activities, including projects within the life sciences industry.
His experience in investment banking provided a foundation in corporate finance, strategic transactions and business management.
Zap Surgical Systems
Between 2019 and 2020, Morris served as interim Chief Financial Officer of Zap Surgical Systems, a company involved in the development of brain radiosurgery technology.
During his tenure, he completed an $81 million growth-equity financing transaction for the company. His responsibilities included financial management and supporting the company's financing activities.
Alwaysraise LLC
In 2020, Morris founded Alwaysraise LLC, an investment and advisory firm specialising in the life sciences sector. Based in San Francisco, California, the firm focuses on investment opportunities, financial advisory work and strategic corporate transactions.
Morris has served as the firm's Managing Partner since its establishment, overseeing its investment and advisory activities.
Entrepreneurship and corporate board involvement
Morris has participated in establishing businesses as a co-founder, including companies operating in the biotechnology and healthcare sectors. One of these businesses continued operating independently, while another was acquired by a Nasdaq-listed company.
His professional involvement in healthcare and medical technology also includes Veris Health and Averto Medical. He previously served on the board of directors of Averto Medical, Inc.
Immix Biopharma
Morris became involved with Immix Biopharma in 2020 after meeting its founder, Ilya Rachman, MD, PhD. Following his initial investment in the company before its initial public offering, he joined the organisation's leadership.
In March 2021, Morris was appointed Chief Financial Officer and a member of the board of directors. He subsequently became President in March 2026.
His executive responsibilities cover several areas of the business, including corporate development, financial operations, business development, investor relations, budgeting, forecasting and financing. He also participates in the company's operational and strategic planning.
Morris has led Immix Biopharma's initial public offering and subsequent financing transactions, which have generated aggregate proceeds exceeding $250 million.
His work supports the company's financial and corporate operations as it advances its biotechnology research and cell therapy development programmes.
Nexcella
Morris is a co-founder of Nexcella, Inc., a biotechnology company associated with the licensing and development pathway of NXC-201, a clinical-stage therapeutic programme that became Immix Biopharma's principal development candidate.
NXC-201 is an investigational BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy being studied for the treatment of AL amyloidosis. Its design incorporates a proprietary CD3ζ signalling domain, a CD8 hinge and a binder-based component described as a "digital filter", intended to reduce non-specific activation.
The treatment is designed to enable engineered immune cells to identify and eliminate abnormal plasma cells responsible for producing disease-associated light chains.
Biotechnology and financial activities
Morris's career combines experience in biotechnology, healthcare investment, corporate finance, investment banking and business development.
His professional activities have included working with corporate executives, investors, financial institutions, board members and strategic partners. At Immix Biopharma, his executive responsibilities include overseeing financial strategy, corporate development and investor relations.
His work in the life sciences sector also includes investment and advisory activities through Alwaysraise LLC and entrepreneurial involvement through Nexcella.
Immix Biopharma's research activities include the development of cell-based immunotherapies and other treatment approaches for AL amyloidosis and additional serious medical conditions.
Professional experience and achievements
Morris's professional background includes:
- Participation in mergers and acquisitions and financial transactions exceeding US$50 billion in aggregate value.
- Experience in cross-border investment banking at Goldman Sachs & Co. and other international financial institutions.
- Completion of an $81 million growth-equity financing transaction for Zap Surgical Systems.
- Leadership of Immix Biopharma's initial public offering and subsequent financing transactions exceeding $250 million.
- Establishment and management of Alwaysraise LLC, a life sciences investment and advisory firm.
- Co-founding Nexcella, Inc., an organisation involved in the development pathway associated with NXC-201.
- Executive responsibilities in corporate finance, investor relations, business development and company operations at Immix Biopharma.
- Previous board membership at Averto Medical, Inc.
